Etira founder Dr. Jung-Mo Ahn highlighted in local press
Ilona Margolis, October 31, 2022
Dallas, Texas. October 31, 2022. We are pleased to share two news articles from Dallas that describe how our brilliant chemist and founder, Dr. Jung-Mo Ahn discovered ERX-41. In his words, Dr. Ahn describes the discovery of ERX-41 as “It’s almost like two elephants are hugging each other, and you’re throwing a pebble to stop them.”
The articles can be accessed here: https://www.dallasnews.com/news/2022/10/31/dallas-researchers-create-molecule-that-kills-hard-to-treat-cancers/
About Etira
EtiraRx is a privately owned Dallas-based biotech startup focused on developing the next generation of cancer therapies. EtiraRx is advancing their first small molecule drug, ERX-315, to phase I clinical trials later this year for patients with metastatic breast cancer.
Learn more at www.etiraRx.com
contact@etirarx.com
Related Post
- One year later, highest almetric score for any paper published in Nature Cancer!
- Positive preclinical data presented at AACR 2023
- Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award
- Preclinical data on TNBC presented at SABCS 2022
- Oncology Times Highlights ERX-41